Ongoing review of cholesterol drug Vytorin

The U.S. Food and Drug Administration (FDA) is informing the public that the agency will conduct a review of Merck and Schering Plough's recent trial once the FDA receives the final study results.

The U.S. Food and Drug Administration issued an Early Communication regarding the agency's ongoing review of Vytorin based on preliminary results from a recently completed study – the Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia (ENHANCE) – on this cholesterol lowering drug. Vytorin contains both Zetia (ezetimibe) and Zocor (simvastatin) in one tablet.

Merck/Schering Plough Pharmaceuticals issued a press release reporting preliminary results of the study and stated that the study demonstrated no significant differences between the combination product and Zocor on the build up of cholesterol plaque in the carotid (neck) arteries. The study was not designed to detect any difference in risk of having a heart attack or stroke between the two treatments. An ongoing trial called -- Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE IT) -- is underway which is designed to evaluate the effect of Vytorin versus Zocor on heart disease and stroke.

This Early Communication is in keeping with the FDA's commitment to inform the public about its ongoing review of drugs. Until the FDA reviews the data, the agency advises patients to talk with their health care providers if they have questions about the ENHANCE study.

Full text of the Early Communication about an Ongoing Data Review for the ENHANCE Study can be found at: http://www.fda.gov/cder/drug/early_comm/ezetimibe_simvastatin.htm.


(Editor compiled and published Ongoing review of cholesterol drug Vytorin at HealthNewsTrack on January 26, 2008 sourced from U.S. Food and Drug Administration - http://www.fda.gov/)

Cholesterol - recent articles and current news stories:

- Safety changes in labeling for cholesterol lowering drugs statins
- Cholesterol lowering drugs statins may help hospitalized influenza patients
- Evacetrapib can increase good cholesterol HDL
- Intensive statin therapy increases risk of diabetes
- New safety recommendations for high dose 80 mg simvastatin

Most related articles:

- Ongoing review of cholesterol drug Vytorin
- Vytorin does not appear to be unsafe - American Heart Association - 9.3
- New safety recommendations for high dose 80 mg simvastatin - 8.1
- Safety changes in labeling for cholesterol lowering drugs statins - 5.5
- FDA will review Daiichi Sankyo, Lilly drug Prasugrel for heart attack - 5

More related articles:

- Cholesterol, Drug, Vytorin, Ezetimibe, Simvastatin, Hypercholesterolemia, ENHANCE, Zetia, Zocor, Plaque, Heart attack, Stroke, Heart disease
- Vytorin does not appear to be unsafe - American Heart Association - 30.3
- New safety recommendations for high dose 80 mg simvastatin - 19.9
- Niacin and statin treatment did not protect heart - 14
- Safety changes in labeling for cholesterol lowering drugs statins - 13.2

Cholesterol related articles:

- Lowering cholesterol reduces heart attack and stroke risk - 4
- Red yeast rice reduce cholesterol in statin intolerant - 3.7
- Mid life cholesterol levels not linked to Alzheimer's disease - 3.6
- Nonstick cookware may elevate cholesterol in children and teens - 3.4
- Combined with exercise, cholesterol increase muscles - 3.2

Cholesterol article/news source:

Read more health articles from U.S. Food and Drug Administration and health articles from USA.

Cholesterol - search related terms:

Cholesterol, Drug, ENHANCE, Ezetimibe, Heart attack, Heart disease, Hypercholesterolemia, Plaque, Simvastatin, Stroke, Vytorin, Zetia, Zocor,
Cholesterol books,

Searched keywords: vytorin (8),

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
0.77